logo
Sign in

MRNA Stock Price, Chart, Stats & News

Moderna, Inc.
Save
20.47B
Market cap
Current P/E
23.04x
Forward P/E

MRNA chart

1M
3M
1Y
5Y
Loading chart...

Fundamentals

Gross margin
14.10%
Operating margin
-158.21%
Pretax margin
-142.46%
Net margin
-145.24%
Effective tax rate
-1.95%
ROA
-22.87%
ROE
-30.15%
D/E
0.22x
Interest coverage ratio
-1537.00x

MRNA valuation

P/E
P/S
10.07x
P/B
2.25x
P/CF
-10.49x
P/FCF
-9.53x
P/OCF
-10.49x
PEG
-0.69x
EV multiple
-7.94x

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.

Similar securities

Based on sector and market capitalization

Report issue